SB 239063 | CAS:193551-21-2

Chemscene社は、高品質な低分子化合物を提供しているメーカーです。
Chemscene社のSB 239063(CAS:193551-21-2)をご紹介します。

※本製品は研究用です。研究用以外には使用できません。

Name:SB 239063; 
Cat. No. :CS-0072
CAS No. :193551-21-2
Formula:C20H21FN4O2
M. Wt. : 368.40
Solubility:10 mM in DMSO

SB 239063 is a potent and selective p38 MAPK inhibitor (IC50 = 44 nM for p38α). SB 239063 displays > 220-fold selectivity over ERK, JNK1 and other kinases; ~ 3-fold more selective than SB 203580. IC50 value: 44 nM ( p38α)Target: p38 MAPKSB 239063 reduces inflammatory cytokine production and is neuroprotective following oral administration in vivo.

Barone FC, et al. SB 239063, a second-generation p38 mitogen-activated protein kinase inhibitor, reduces brain injury and neurological deficits in cerebral focal ischemia.J Pharmacol Exp Ther. 2001 Feb;296(2):312-21. Underwood et al (2000) SB 239063, a potent p38 MAP kinase inhibitor, reduces inflammatory cytokine production, airways eosinophil infiltration, and persistence. J.Pharmacol.Exp.Ther. 293 281. Ward KW, et al. SB-239063, a potent and selective inhibitor of p38 map kinase: preclinical pharmacokinetics and species-specific reversible isomerization.Pharm Res. 2001 Sep;18(9):1336-44. Legos et al (2002) The selective p38 inhibitor SB-239063 protects primary neurons from mild to moderate excitotoxic injury. Eur.J.Pharmacol. 447 37. Matthew Huentelman, et al. Methods of treating memory loss and enhancing memory performance. US 20120245188 A1. Bison S, et al. Effect of the p38 MAPK inhibitor SB-239063 on Lipopolysaccharide-induced psychomotor retardation and peripheral biomarker alterations in rats.Eur J Pharmacol. 2011 Jul 1;661(1-3):49-56. Epub 2011 Apr 27.